详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Orthopaedic Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China [2]School of Biomedical Sciences, The University of Western Australia, Perth, Western, Australia [3]The Lab of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [4]Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi, China [5]Department of Biomedical Materials Science, Third Military Medical University, Chongqing, China

出处：

DOI：

ISSN：

关键词： Ca2+ oscillation evodiamine NF-κB osteoclast osteoporosis ovariectomy

摘要：

Postmenopausal osteoporosis (PMO) is a progressive bone disease characterized by the over-production and activation of osteoclasts in elderly women. In our study, we investigated the anti-osteoclastogenic effect of evodiamine (EVO) in vivo and in vitro, as well as the underlying mechanism. By using an in vitro bone marrow macrophage (BMM)-derived osteoclast culture system, we found that EVO inhibited osteoclast formation, hydroxyapatite resorption and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene and protein expression. Mechanistically, we found that EVO inhibited the degradation and RANKL-induced transcriptional activity of IκBα. RANKL-induced Ca2+ oscillations were also abrogated by EVO. In vivo, an ovariectomized (OVX) mouse model was established to mimic PMO, and OVX mice received oral administration of either EVO (10 mg/kg) or saline every other day. We found that EVO can attenuate bone loss in OVX mice by inhibiting osteoclastogenesis. Taken together, our findings suggest that EVO suppresses RANKL-induced osteoclastogenesis through NF-κB and calcium signalling pathways and has potential value as a therapeutic agent for PMO. © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 3 区细胞生物学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区细胞生物学 3 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Orthopaedic Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China [2]School of Biomedical Sciences, The University of Western Australia, Perth, Western, Australia

共同第一作者：

通讯作者：

通讯机构： [1]Department of Orthopaedic Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China [2]School of Biomedical Sciences, The University of Western Australia, Perth, Western, Australia [*1]School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia [*2]Department of Orthopaedic Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.

文献详情

相关文献